.Consensus on whole-process pharmaceutical care for iodine contrast medium[J].ZHONGGUO YAOFANG,2024,35(01):1-9. DOI: 10.6039/j.issn.1001-0408.2024.01.01.
Consensus on whole-process pharmaceutical care for iodine contrast medium
To explore the whole-process pharmaceutical care model of iodine contrast medium and promote the rational clinical use of iodine contrast medium.
METHODS
2
Clinical Professional Committee on Rational Drug Use of China Medical Education Association and Expert Committee on Drug Evaluation and Clinical Research of Guangdong Pharmaceutical Association organized domestic experts to establish a working group on the
Consensus on the whole-process pharmaceutical care for iodine contrast medium
. The working group conducted literature searches, evidence-based analysis, and discussions on the development process, indications, contraindications, adverse drug reactions, drug interactions, drug use for special population, pharmaceutical care, and other key topics to summarize the content and process of the whole-process pharmaceutical care for iodine contrast medium. This consensus was ultimately formed.
RESULTS
2
The consensus on whole-process pharmaceutical care for iodine contrast medium included an evaluation of the patient, renal function, combined drug use, and hydration regimen before examination, the presence of contrast agent extravasation or suspected acute adverse reactions during examination, observation time points and follow-up after examination, and the presentation of specific work in each stage through pharmaceutical care flowchart. The medication monitoring record form was also formed to record the work situation.
CONCLUSIONS
2
The consensus has established a whole-process pharmaceutical care system for iodine contrast medium, providing scientific evidence for clinical physicians and nursing staff in the rational use of such special drugs, and also serving as a reference for pharmacists in providing related pharmaceutical care.
关键词
碘对比剂合理用药药物不良反应药学服务全流程共识
Keywords
rational drug useadverse drug reactionspharmaceutical carewhole-processconsensus
MAO Y J,LI Y M,ZENG X H. Nursing practice manual for intravenous injection of iodine contrast agent[M]. Shanghai:Shanghai Scientific & Technical Publishers,2020:12-16.
ACR Committee on Drugs and Contrast Media. ACR manual on contrast media.[M]. 2023 edition. Washington:American College of Radiology,2021:5-55.
Radiology European Society of Urogenital. ESUR guidelines on contrast agents[M]. Vienna:ESUR Guidelines on Contrast Agents,2018:6-30.
Chinese Society of Clinical Pharmacy,Hospital Pharmacy Committee of the Chinese Pharmaceutical Association,Nephrology Branch of the Chinese Medical Association.Expert consensus on prevention and treatment of iodine contrast media-induced acute kidney injury[J]. Chin J Nephrol,2022,38(3):265-288.
WEI Y,HE Z,ZHANG C,et al. Cost-minimization analysis of multidose and single-dose packaging of contrast media for contrast-enhanced CT:results from real-world data in China[J]. AJR Am J Roentgenol,2020,215:(1):5-14.
MACDONALD D B,HURRELL C D,COSTA A F,et al. Canadian Association of Radiologists guidance on contrast-associated acute kidney injury[J]. Can J Kidney Health Dis,2022,9:20543581221097455.
PERNER A,PROWLE J,JOANNIDIS M,et al. Fluid management in acute kidney injury[J]. Intensive Care Med,2017,43(6):807-815.
WHITING P,MORDEN A,TOMLINSON L A,et al. What are the risks and benefits of temporarily disconti- nuing medications to prevent acute kidney injury? A systematic review and meta-analysis[J]. BMJ Open,2017,7(4):e012674.
ORLACCHIO A,GUASTONI C,BERETTA G D,et al. SIRM-SIN-AIOM:appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM),Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)[J]. Radiol Med,2022,127(5):534-542.
HWANG E J,SHIN C I,CHOI Y H,et al. Frequency,outcome,and risk factors of contrast media extravasation in 142 651 intravenous contrast-enhanced CT scans[J]. Eur Radiol,2018,28(12):5368-5375.
PLUMB A A,MURPHY G. The use of central venous catheters for intravenous contrast injection for CT examinations[J]. Br J Radiol,2011,84(999):197-203.
Contrast Media Safety Committee of the Radiology Branch of the Chinese Medical Association. Guide to the use of iodine contrast agents:2nd edition [J]. Natl Med J China,2014,94(43):3363-3369.
YAMAGUCHI K,KATAYAMA H,TAKASHIMA T, et al. Prediction of severe adverse reactions to ionic and nonionic contrast media in Japan:evaluation of pretesting. A report from the Japanese Committee on the Safety of Contrast Media[J]. Radiology,1991,178(2):363-367.
LASSER E C,BERRY C C,MISHKIN M M,et al. Pretreatment with corticosteroids to prevent adverse reactions to nonionic contrast media[J]. AJR Am J Roentgenol,1994,162(3):523-526.
DAVENPORT M S,KHALATBARI S,COHAN R H, et al. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material:risk stratification by using estimated glomerular filtration rate[J]. Radiology,2013,268(3):719-728.
MCDONALD R J,MCDONALD J S,BIDA J P,et al. Intravenous contrast material-induced nephropathy:causal or coincident phenomenon?[J]. Radiology,2016,278(1):306.
MCDONALD J S,MCDONALD R J,CARTER R E, et al. Risk of intravenous contrast material-mediated acute kidney injury:a propensity score-matched study stratified by baseline-estimated glomerular filtration rate[J]. Radiology,2014,271(1):65-73.
Quality Control and Safety Management Committee of the Radiology Branch of the Chinese Medical Association.Expert consensus of iodinated contrast agent use in patients with renal diseases[J]. Chin J Radiol,2021,55(6):580-590.
HIREMATH S,AKBARI A,SHABANA W,et al. Prevention of contrast-induced acute kidney injury:is simple oral hydration similar to intravenous? A systematic review of the evidence[J]. PLoS One,2013,8(3):e60009.
Consensus on whole-process pharmaceutical care for gadolinium-based contrast agents
Quality evaluation of Chinese and global guidelines/consensus for TDM of anti-TNF-α agents in patients with inflammatory bowel disease
Analysis and evaluation of the application of polymyxin B in inpatients based on clinical guidelines and consensuses
Survey analysis of influential factors of medication compliance and adverse drug reactions of home-based patients with severe mental disorders in Jinshan district of Shanghai
Related Author
Clinical Professional Committee on Rational Drug Use of China Medical Education Association
Expert Committee on Drug Evaluation and Clinical Research of Guangdong Pharmaceutical Association
王勇
喻珊珊
China Medical Education Association Rational Drug Use Professional Committee
Wang Yong
Yu Shanshan
JIN Tanghui
Related Institution
Dept. of Pharmacy, the First Affiliated Hospital of Soochow University
Dept. of Gastroenterology, the First Affiliated Hospital of Soochow University
Dept. of Pharmacy, Tianjin Medical University General Hospital
Dept. of Pharmacy, Jinshan Branch of Shanghai Sixth People’s Hospital
Shanghai Jinshan District Zhujing Community Health Service Center